Amengual JE, et al. - Based on synergy of the combination of romidepsin and pralatrexate in preclinical models of peripheral T-cell lymphomas (PTCL), a phase I study investigating the combination in patients with relapsed/refractory lymphoma was performed. The combination of romidepsin and pralatrexate was safe and well tolerated in these patients. The combination resulted in an overall response rate of 71% (10/14) (4/14 CR) in patients with relapsed/refractory T-cell lymphoma.